This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
ReNeuron Group Inkomsten in het verleden
Verleden criteriumcontroles 0/6
ReNeuron Group has been growing earnings at an average annual rate of 17.8%, while the Biotechs industry saw earnings growing at 15.7% annually. Revenues have been declining at an average rate of 51.6% per year.
Belangrijke informatie
17.8%
Groei van de winst
30.7%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 11.5% |
Inkomstengroei | -51.6% |
Rendement op eigen vermogen | -209.5% |
Nettomarge | -2,037.3% |
Volgende winstupdate | 30 May 2024 |
Recente prestatie-updates uit het verleden
Recent updates
We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth Carefully
Jul 15We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn Rate
Jan 22Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In Growth
Oct 12Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?
Jun 04Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?
Jan 12Here's What We Learned About The CEO Pay At ReNeuron Group plc (LON:RENE)
Nov 20Opbrengsten en kosten
Hoe ReNeuron Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 23 | 0 | -5 | 3 | 0 |
30 Jun 23 | 0 | -5 | 3 | 0 |
31 Mar 23 | 1 | -5 | 3 | 0 |
31 Dec 22 | 1 | -7 | 3 | 0 |
30 Sep 22 | 1 | -8 | 4 | 0 |
30 Jun 22 | 1 | -9 | 4 | 0 |
31 Mar 22 | 0 | -10 | 4 | 0 |
31 Dec 21 | 0 | -10 | 4 | 0 |
30 Sep 21 | 0 | -9 | 4 | 0 |
30 Jun 21 | 0 | -10 | 4 | 0 |
31 Mar 21 | 0 | -11 | 4 | 0 |
31 Dec 20 | 0 | -13 | 4 | 0 |
30 Sep 20 | 0 | -15 | 4 | 0 |
30 Jun 20 | 3 | -13 | 4 | 0 |
31 Mar 20 | 6 | -11 | 4 | 0 |
31 Dec 19 | 6 | -12 | 5 | 0 |
30 Sep 19 | 6 | -13 | 5 | 0 |
30 Jun 19 | 5 | -14 | 5 | 0 |
31 Mar 19 | 3 | -14 | 5 | 0 |
31 Dec 18 | 3 | -14 | 5 | 0 |
30 Sep 18 | 3 | -13 | 5 | 0 |
30 Jun 18 | 2 | -16 | 5 | 0 |
31 Mar 18 | 1 | -18 | 5 | 0 |
31 Dec 17 | 1 | -18 | 4 | 0 |
30 Sep 17 | 1 | -17 | 4 | 0 |
30 Jun 17 | 1 | -17 | 4 | 0 |
31 Mar 17 | 1 | -16 | 4 | 0 |
31 Dec 16 | 1 | -15 | 4 | 0 |
30 Sep 16 | 1 | -15 | 4 | 0 |
30 Jun 16 | 1 | -13 | 4 | 0 |
31 Mar 16 | 1 | -11 | 4 | 0 |
31 Dec 15 | 1 | -10 | 4 | 0 |
30 Sep 15 | 1 | -9 | 4 | 0 |
30 Jun 15 | 1 | -9 | 4 | 0 |
31 Mar 15 | 1 | -9 | 4 | 0 |
31 Dec 14 | 1 | -8 | 3 | 0 |
30 Sep 14 | 1 | -8 | 3 | 0 |
30 Jun 14 | 1 | -8 | 3 | 0 |
31 Mar 14 | 1 | -7 | 3 | 0 |
31 Dec 13 | 0 | -7 | 2 | -1 |
30 Sep 13 | 0 | -7 | 2 | -2 |
30 Jun 13 | 0 | -6 | 2 | -1 |
Kwaliteitswinsten: RENE is currently unprofitable.
Groeiende winstmarge: RENE is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: RENE is unprofitable, but has reduced losses over the past 5 years at a rate of 17.8% per year.
Versnelling van de groei: Unable to compare RENE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: RENE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: RENE has a negative Return on Equity (-209.54%), as it is currently unprofitable.